Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company's lead drug candidate for benign prostatic hyperplasia (BPH) Fexapotide Triflutate (FT) has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. Currently, the Company will soon be filing for approval in major economies around the world, including the United States and Europe.
Company profile
Ticker
NYMX
Exchange
Website
CEO
Paul Averback
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
NYMX stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
12 May 23
20-F
2022 FY
Annual report (foreign)
2 May 23
NT 20-F
Notice of late annual filing (foreign)
31 Mar 23
6-K
Current report (foreign)
6 Jan 23
6-K/A
Current report (foreign) (amended)
16 Nov 22
6-K/A
Current report (foreign) (amended)
16 Nov 22
6-K
Current report (foreign)
14 Nov 22
6-K
Current report (foreign)
10 Nov 22
6-K
Current report (foreign)
15 Aug 22
6-K
Current report (foreign)
7 Jul 22
Latest ownership filings
4/A
James George Robinson
18 May 23
4
James George Robinson
6 May 22
4
James George Robinson
27 Apr 21
4
James George Robinson
12 Jul 19
4
James George Robinson
10 Jul 19
4
James George Robinson
9 Jul 19
4
James George Robinson
3 Jul 19
4
James George Robinson
2 Jul 19
4
James George Robinson
1 Jul 19
4
James George Robinson
28 Jun 19
Financial summary
| Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Institutional ownership, Q3 2021
| 13F holders | Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 0.00 |
| Total shares | 0.00 |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 25 Apr 23 | Robinson James George | Common Stock | Buy | Acquire P | No | No | 0.45 | 40,000 | 18.00 k | 4,742,065 |
| 2 May 22 | Robinson James George | Common Stock | Buy | Acquire P | No | No | 1.65 | 1,151,515 | 1.90 mm | 4,702,065 |
| 2 May 22 | Robinson James George | Warrant Common stock | Buy | Acquire P | No | No | 2 | 1,151,515 | 2.30 mm | 1,151,515 |
News
Nymox Provides Current Update
10 May 23
12 Health Care Stocks Moving In Monday's Pre-Market Session
27 Mar 23
Nymox Announces Appointment Of Christopher R. Riley As Chief Financial Officer
21 Mar 23
Nymox Officially Granted Extension Until July 3, 2023 To Regain Listing Requirements
15 Mar 23
12 Health Care Stocks Moving In Tuesday's After-Market Session
14 Mar 23